We further analyzed the association of EZH2 expression with the efficacy of anti-EGFR therapy in patients with colorectal cancer with no mutations in KRAS (codon 61/146), NRAS (codon 12/13/61), or BRAF (codon 600). Here, BRAF is linked to colorectal cancer.